Banque de Luxembourg S.A. Makes New $727,000 Investment in Boston Scientific Co. (NYSE:BSX)

Banque de Luxembourg S.A. bought a new position in Boston Scientific Co. (NYSE:BSX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,106 shares of the medical equipment provider's stock, valued at approximately $727,000. Boston Scientific comprises about 0.4% of Banque de Luxembourg S.A.'s investment portfolio, making the stock its 28th largest position.

A number of other large investors have also made changes to their positions in BSX. World Investment Advisors LLC grew its position in Boston Scientific by 50.9% during the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider's stock valued at $979,000 after buying an additional 3,939 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $1,175,000. Synovus Financial Corp raised its holdings in Boston Scientific by 7.1% in the 3rd quarter. Synovus Financial Corp now owns 17,518 shares of the medical equipment provider's stock worth $1,468,000 after purchasing an additional 1,167 shares during the period. B. Riley Wealth Advisors Inc. raised its holdings in Boston Scientific by 36.2% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 15,553 shares of the medical equipment provider's stock worth $1,303,000 after purchasing an additional 4,136 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Boston Scientific by 5.9% during the third quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider's stock valued at $168,475,000 after purchasing an additional 111,724 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Down 0.0 %

Shares of BSX stock traded down $0.02 on Tuesday, reaching $104.22. 5,174,388 shares of the company's stock were exchanged, compared to its average volume of 6,341,116. The company's fifty day simple moving average is $98.71 and its 200 day simple moving average is $95.66. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $154.15 billion, a PE ratio of 83.38, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period last year, the company earned $0.56 earnings per share. As a group, analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 307,025 shares of company stock worth $31,742,060 in the last three months. Corporate insiders own 0.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. UBS Group boosted their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Needham & Company LLC boosted their target price on Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Finally, Barclays raised their price target on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Twenty-three analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus price target of $114.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.